Drug Profile
Afimoxifene - BHR Pharma
Alternative Names: 4-Hydroxytamoxifen; 4-Hydroxytamoxifen (afimoxifene) gel; 4-Hydroxytamoxifen gel; 4-OH tamoxifen; 4-OHT; TamoGelLatest Information Update: 08 Mar 2022
Price :
$50
*
At a glance
- Originator Besins International
- Developer Besins Healthcare; BHR Pharma
- Class Antineoplastics; Hydroxytestosterones; Non-opioid analgesics
- Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer
- No development reported Breast pain; Gynaecomastia; Hyperplasia
- Discontinued Keloids
Most Recent Events
- 08 Mar 2022 No development reported - Phase-III for Hyperplasia in Spain, Germany, USA (Topical)
- 03 Feb 2020 Afimoxifene is still in phase III trials for Hyperplasia in USA, Germany and Spain (NCT03199963)
- 04 Jul 2019 Northwestern University and National Cancer Institute plan a phase II trial in Breast cancer (NCT04009044; NCI-2019-03771; NU 18B05)